The first batch of Zytux™, the biosimilar, with generic name of Rituximab was launched in Iran market on 18 January 2014 by Aryogen Biopharma.
Production of this drug is unique in a way that it is the first therapeutically monoclonal antibody produced in Iran from the base. The whole production process, from the cell bank to formulation, filling and packaging is done by Iranian biopharmaceutical professionals in Aryogen.
Zytux™ is marketed after passing the clinical trial tests on a large group of patients. Clinical studies were approved by the Ministry of health and Educational system, Bureau of Biologics in Food and Drug Administration, Food and Drug control reference Lab and the third party laboratories.
This drug is used to treat cancer of the white blood system such as leukemias and lymphomas including non-Hodgkin's lymphoma and autoimmune diseases like rheumatoid arthritis. For more information, please visit the following pages: